BIOGEN INC. Loss Contingency, Estimate of Possible Loss
BIOGEN INC. (BIIB) had Loss Contingency, Estimate of Possible Loss of $49.90 million as of 2024-06-30, per its 10-Q filed 2025-05-01.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2025-05-01
- 2012-12-31: Loss Contingency, Estimate of Possible Loss 30.70M EUR.
- 2011-12-31: Loss Contingency, Estimate of Possible Loss 30.70M EUR.
EUR
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2012-12-31 | 30.70M EUR 10-Q · filed 2013-04-25 |
| 2011-12-31 | 30.70M EUR 10-Q · filed 2012-10-25 |
USD
| Period end | Loss Contingency, Estimate of Possible Loss |
|---|---|
| 2024-06-30 | $49.90M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $49.90M 10-Q · filed 2024-10-30 |
| 2023-09-30 | $49.90M 10-Q · filed 2024-08-01 |
| 2023-06-30 | $49.90M 10-K · filed 2025-02-12 |
| 2021-12-31 | $200.00M 10-Q · filed 2023-04-25 |
| 2021-07-15 | $981.10M 10-Q · filed 2022-05-03 |
| 2020-12-31 | $200.00M 10-Q · filed 2025-05-01 |
| 2019-12-31 | $200.00M 10-K · filed 2025-02-12 |
| 2011-06-30 | $50.00M 10-Q · filed 2012-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |